Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial
Revista Española de Cardiología (English Edition) · 2026
DOI: 10.1016/j.rec.2026.03.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Revista Española de Cardiología (English Edition), 2026. Verfasst von Sergio Raposeiras-Roubín und 24 weiteren Autor:innen. Beteiligte Einrichtung: Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Servicio de Cardiología, Hospital Universitario Alvaro Cunqueir…. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Stroke Volume, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Centro Nacional de Investigaciones Cardiovasculares Carlos III, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades.
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Recent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may influence the effect of beta-blockers. METHODS: In this prespecified subgroup analysis of the REBOOT trial, which randomized invasively managed MI patients with LVEF> 40% to beta-blockers or control, we evaluated differences in long-term effects of the intervention between STEMI (n=4296) and NSTEMI (n=4142). The primary endpoint was a composite of all-cause death, reinfarction, or heart failure hospitalization over a median follow-up of 3.7 years. RESULTS: The primary endpoint and its components occurred more frequently in NSTEMI than in STEMI. A significant interaction between MI type and beta-blocker allocation was observed (P=.027). Among STEMI patients, beta-blockers were associated with a higher incidence of the primary endpoint (HR, 1.27; 95%CI, 1.00-1.62), whereas NSTEMI patients assigned to beta-blockers showed no effect (HR, 0.89; 95%CI, 0.72-1.10). Notably, NSTEMI patients with mildly reduced LVEF (40% to 50%) on beta-blockers experienced significantly fewer events than controls. CONCLUSIONS: The absence of clear clinical benefit from beta-blockers in invasively managed MI patients with preserved LVEF was consistent across STEMI and NSTEMI. The observed interaction by infarct type is exploratory and should not be interpreted as definitive evidence of harm associated with beta-blocker therapy in patients with STEMI and preserved LVEF. NSTEMI patients with mildly reduced LVEF may benefit from beta-blockers, warranting further investigation. (ClinicalTrials.gov: NCT03596385).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Servicio de Cardiología, Hospital Universitario Alvaro Cunqueiro, Vigo, Pontevedra, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Cardiología, Hospital Universitario Reina Sofía, Instituto Maimónides de Inv…
- Dipartimento di Lesione Acuta Cerebrale e Cardiovascolare, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Departamento de Medicina Interna, Universidad de La Laguna, La Laguna, Santa Cruz de Ten…
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Cardiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación…
Förderung
- Centro Nacional de Investigaciones Cardiovasculares Carlos III
- Instituto de Salud Carlos III
- Ministerio de Ciencia, Innovación y Universidades
Zitieren
APA
Raposeiras-Roubín, S., Anguita, M., Latini, R., Domínguez-Rodríguez, A., Barrabés, J. A., Sánchez, P. L., Ottani, F., Pocock, S., Owen, R., Cristobo, P., Gómez-Talavera, S., Staszewsky, L., Escalera, N., Fernández-Vázquez, F., Bianco, M., Prada-Delgado, Ó., Pérez-García, C. N., Pelizzoni, V., Navarro, F., …, & Ibáñez, B. (2026). Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2026.03.007
Vancouver
Raposeiras-Roubín S, Anguita M, Latini R, Domínguez-Rodríguez A, Barrabés JA, Sánchez PL, et al. Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial. Revista Española de Cardiología (English Edition). 2026. doi:10.1016/j.rec.2026.03.007
BibTeX
@article{RaposeirasRoubn2026,
author = {Raposeiras-Roubín, Sergio and Anguita, Manuel and Latini, Roberto and Domínguez-Rodríguez, Alberto and Barrabés, José A and Sánchez, Pedro L and Ottani, Filippo and Pocock, Stuart and Owen, Ruth and Cristobo, Pablo and Gómez-Talavera, Sandra and Staszewsky, Lidia and Escalera, Noemí and Fernández-Vázquez, Felipe and Bianco, Matteo and Prada-Delgado, Óscar and Pérez-García, Carlos Nicolás and Pelizzoni, Valentina and Navarro, Felipe and Pérez-Rivera, José-Ángel and Martín-Gorria, Gonzalo and Vetrano, Alfredo and Fuster, Valentín and Rosselló, Xavier and Ibáñez, Borja},
title = {Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial},
journal = {Revista Española de Cardiología (English Edition)},
year = {2026},
doi = {10.1016/j.rec.2026.03.007}
}
EUVIMED